Announcements
- New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries
- Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility
- Esperion to Participate in Upcoming June Investor Conferences
- First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
- Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
- Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Esperion Reports First Quarter 2024 Financial Results
- Esperion to Participate in Upcoming May Investor Conferences
- Esperion to Report First Quarter 2024 Financial Results on May 7
More ▼
Key statistics
As of last trade Esperion Therapeutics Inc (0ET:FRA) traded at 2.02, -32.46% below its 52-week high of 2.99, set on Apr 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.02 |
---|---|
High | 2.02 |
Low | 2.02 |
Bid | 2.02 |
Offer | 2.42 |
Previous close | 2.00 |
Average volume | 2.61k |
---|---|
Shares outstanding | 189.46m |
Free float | 188.48m |
P/E (TTM) | -- |
Market cap | 443.34m USD |
EPS (TTM) | -1.00 USD |
Data delayed at least 15 minutes, as of Jul 24 2024 07:14 BST.
More ▼